2-(3-Fluoro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98.0%, 250mg

BENZYL 3-METHYLENEPIPERIDINE-1-CARBOXYLATE, 95.0%, 50g

(2-TERT-BUTYL-PHENOXY)ACETONITRILE, 97.0%, 5g

E-Plan phase EPLPH 20x/0.40 objective. Working distance 1.85 mm

((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHANOL, 98%, 250mg

Sample beakers with screw closure with graduation and labelling area, 120 ml, Sterile, 250 Piece(s)

(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one, 95.0%, 1g

6-BROMO-7-METHOXYIMIDAZO[1,2-A]PYRIDINE, 95.0%, 100mg

1-(4-(Trifluoromethyl)phenyl)propan-1-amine hydrochloride, 97%, 250mg

Methyl cis-1-Boc-4-hydroxy-D-prolinate, 97.0%, 1g

1,3-Dimethyl-4,4-difluoropiperidine, 25g

Phenazine-1,6-dicarboxylic acid, 95%, 50mg

ETHYL 7-BROMO-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE-2-CARBOXYLATE, 95.0%, 100mg